Log in

RegulatoryBusinessLine

Natco Pharma gets USFDA EIR for Visakhapatnam plant

Negative-322 sources

GreyOak summary

Natco Pharma received an Establishment Inspection Report (EIR) from the US FDA regarding its FDF manufacturing plant in Parawada, Visakhapatnam. The inspection, conducted between August 17 and 21, 2026, resulted in four observations listed in Form-483. The FDA classified the inspection findings as Voluntary Action Indicated (VAI).

What it affects

Source

Reported by BusinessLine

  • Business Today
  • BusinessLine

More Natco Pharma news

All Natco Pharma news →

The company today

Price, day change, sector and market cap of the companies this story names
CompanyPriceDay changeSectorMarket cap
Natco PharmaNATCOPHARM · NSE₹818.85−0.38%Healthcare₹16,063 crore

Prices as of ; the last session's close when the market is shut. Research, not investment advice.

Latest market news

News Intelligence →

We use cookies

Essential cookies keep GreyOak secure and functional. Optional cookies help improve your experience and platform performance. You can update your preferences anytime.

Cookie Policy